Literature DB >> 24142711

Suppression of amino acid transporter LAT3 expression on proliferation of K562 cells.

Si-Miao Xu1, Kun Tang1, Li Meng1, Yi Tang2.   

Abstract

The activity of the mTOR pathway is frequently increased in acute myeloid leukemia, and is tightly related with cellular proliferation. Leucine is tightly linked to the mTOR pathway and can activate it, thereby stimulating cellular proliferation. LAT3 is a major transporter for leucine, and suppression of its expression can reduce cell proliferation. Here, we show that suppression of LAT3 expression can reduce proliferation of the acute leukemia cell line, K562. We investigated the mRNA and protein expression of LAT3 in several leukemia cell lines and normal peripheral blood mononuclear cells (PBMNCs) using RT-PCR and Western blotting. We also evaluated cell viability using a methyl thiazolyl tetrazolium (MTT) assay after blocking LAT3 expression with either shRNA targeted to LAT3 or a small molecular inhibitor BCH (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid). LAT3 mRNA and protein expression was detected in leukemia cell lines, but not in normal PBMNCs. Using K562 cells, it was found that cellular proliferation and mTOR pathway activity were significantly reduced when LAT3 was blocked with either shRNA or BCH. Our results suggest that leukemia cell proliferation can be significantly suppressed by blocking LAT3. This finding may lead to a new strategy to develop clinical therapy for the treatment of acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24142711     DOI: 10.1007/s11596-013-1171-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

1.  Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.

Authors:  Qian Wang; Charles G Bailey; Cynthia Ng; Jessamy Tiffen; Annora Thoeng; Vineet Minhas; Melanie L Lehman; Stephen C Hendy; Grant Buchanan; Colleen C Nelson; John E J Rasko; Jeff Holst
Journal:  Cancer Res       Date:  2011-10-17       Impact factor: 12.701

2.  Bidirectional transport of amino acids regulates mTOR and autophagy.

Authors:  Paul Nicklin; Philip Bergman; Bailin Zhang; Ellen Triantafellow; Henry Wang; Beat Nyfeler; Haidi Yang; Marc Hild; Charles Kung; Christopher Wilson; Vic E Myer; Jeffrey P MacKeigan; Jeffrey A Porter; Y Karen Wang; Lewis C Cantley; Peter M Finan; Leon O Murphy
Journal:  Cell       Date:  2009-02-06       Impact factor: 41.582

3.  Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines.

Authors:  O Yanagida; Y Kanai; A Chairoungdua; D K Kim; H Segawa; T Nii; S H Cha; H Matsuo; J Fukushima; Y Fukasawa; Y Tani; Y Taketani; H Uchino; J Y Kim; J Inatomi; I Okayasu; K Miyamoto; E Takeda; T Goya; H Endou
Journal:  Biochim Biophys Acta       Date:  2001-10-01

4.  Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells.

Authors:  David B Shennan; Jean Thomson
Journal:  Oncol Rep       Date:  2008-10       Impact factor: 3.906

5.  L-type amino acid transporter 1 inhibitors inhibit tumor cell growth.

Authors:  Koji Oda; Noriko Hosoda; Hiroshi Endo; Kunio Saito; Kenji Tsujihara; Michio Yamamura; Takeshi Sakata; Naohiko Anzai; Michael F Wempe; Yoshikatsu Kanai; Hitoshi Endou
Journal:  Cancer Sci       Date:  2009-10-08       Impact factor: 6.716

6.  Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters.

Authors:  Ellappan Babu; Yoshikatsu Kanai; Arthit Chairoungdua; Do Kyung Kim; Yuji Iribe; Sahatchai Tangtrongsup; Promsuk Jutabha; Yuewei Li; Nesar Ahmed; Shinichi Sakamoto; Naohiko Anzai; Seishi Nagamori; Hitoshi Endou
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

7.  System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.

Authors:  Kohichi Yamauchi; Hiroyuki Sakurai; Toru Kimura; Pattama Wiriyasermkul; Shushi Nagamori; Yoshikatsu Kanai; Naoyuki Kohno
Journal:  Cancer Lett       Date:  2008-12-05       Impact factor: 8.679

8.  L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.

Authors:  Takeshi Sakata; Golam Ferdous; Tomoko Tsuruta; Takefumi Satoh; Shiro Baba; Tomoko Muto; Akinori Ueno; Yoshikatsu Kanai; Hitoshi Endou; Isao Okayasu
Journal:  Pathol Int       Date:  2009-01       Impact factor: 2.534

Review 9.  Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.

Authors:  A M Martelli; P L Tazzari; C Evangelisti; F Chiarini; W L Blalock; A M Billi; L Manzoli; J A McCubrey; L Cocco
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

10.  Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.

Authors:  S Zhao; M Konopleva; M Cabreira-Hansen; Z Xie; W Hu; M Milella; Z Estrov; G B Mills; M Andreeff
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

  10 in total
  4 in total

Review 1.  L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.

Authors:  Qian Wang; Jeff Holst
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

2.  SLC38A1 promotes proliferation and migration of human colorectal cancer cells.

Authors:  Fen-Fang Zhou; Wei Xie; Shuang-Qian Chen; Xiao-Kang Wang; Qing Liu; Xue-Kai Pan; Fei Su; Mao-Hui Feng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-02-22

3.  Impact of L-type amino acid transporter 3 on the prognosis of hepatocellular carcinoma.

Authors:  Baasansvren Selenge; Shinichiro Yamada; Yuji Morine; Tetsuya Ikemoto; Yu Saito; Chie Takasu; Hiroki Teraoku; Mitsuo Shimada
Journal:  Oncol Lett       Date:  2022-09-30       Impact factor: 3.111

Review 4.  Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.

Authors:  Livingstone Fultang; Luciana Gneo; Carmela De Santo; Francis J Mussai
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.